TGen Drug Development partners with Horizon Discovery to offer an integrated personalized medicine service

The partnership will create a beginning-to-end solution for pharmaceutical and biotechnology companies to more rationally design and tailor their drugs to specific patient populations based on the unique genetic variations that define a given disease.

TD2 will use Horizon’s panel of more than 200 genetically-defined human isogenic cell-lines – designed to accurately mirror cancer patient genetics – in its comprehensive pre-clinical service as a prelude to performing selected in-house clinical trials. This will provide clients with a fully integrated drug discovery service that will accelerate the isolation and optimization of appropriately targeted therapeutic agents and attain their rapid market approval. And it will save time and money in the development of more effective cancer treatments.